Cordyceps Sunshine Biotech Holdings (RAJAF) Short term Debt (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Short term Debt history runs 5 years deep, the most recent figure standing at $465233.0 for Q4 2025.

• In Q4 2025, Short term Debt rose 3.81% year-over-year to $465233.0; the TTM figure through Dec 2025 stood at $465233.0 (up 3.81% YoY), while the FY2025 annual figure was $465233.0, up 3.81% from the prior year.
• Short term Debt was $465233.0 for Q4 2025 at Cordyceps Sunshine Biotech Holdings, up from $448155.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $1.6 million in Q4 2021 to a low of $414000.0 in Q4 2022.
• Historically, Short term Debt has averaged $724668.0 across 4 years, with a median of $456694.0 in 2024.
• The sharpest annual moves came in 2021 and 2022: Short term Debt rose 22.23% in 2021, then slumped 73.65% in 2022.
• A 4-year view of Short term Debt shows it stood at $1.6 million in 2021, then plunged by 73.65% to $414000.0 in 2022, then rose by 8.25% to $448155.0 in 2024, then gained by 3.81% to $465233.0 in 2025.
• The last three Short term Debt figures came in at $465233.0 (Q4 2025), $448155.0 (Q4 2024), and $414000.0 (Q4 2022), per Business Quant data.